Ultra Sensitive Digital ELISA
Overview and technology
Detection of blood/CSF proteins for disease prognosis is used in both research and the clinic but many biomarkers exist under the detection threshold of conventional methods such as ELISA. Quanterix’s SIMOA (Single Molecule Assay) uses a unique array that creates hundreds of thousands of fL volume reactions allowing detection of sub pg/ml concentrations. This technology is revolutionizing many fields of research such as neurodegenerative diseases, inflammation, infectious disease (COVID-19), and more.
The first field to be majorly impacted was neurology, where new biomarkers such as NF-Light, p-Tau181, GFAP, Abeta40 Abeta42 that were found very efficient in early-stage detection of Alzheimer’s, dementia, Parkinson’s disease, TBI, and more.
During COVID-19 outbreak, SIMOA technology was used to decipher the cytokine storm and advanced serology research.
SIMOA technology opens countless possibilities for understanding complex biological processes by discovering and measuring key factors that were undetectable.